Greet Beets
Tibotec
4 Papers
43 Citations
Greet Beets is an academic researcher from Tibotec. The author has contributed to research in topics: Etravirine & Internal medicine. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Adriano Lazzarin,Thomas B. Campbell,Bonaventura Clotet,Margaret Johnson,Christine Katlama,Arend Moll,William J. Towner,Benoit Trottier,Monika Peeters,Johan Vingerhoets,Goedele De Smedt,Benny Baeten,Greet Beets,Rekha Sinha,Brian Woodfall +14 more
TL;DR: In treatment-experienced patients with NNRTI resistance, treatment with TMC 125 achieved better virological suppression at week 24 than did placebo, and the safety and tolerability profile of TMC125 was generally comparable with placebo.
526
•Journal Article
Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.
Thomas N. Kakuda,Monika Schöller-Gyüre,Cassy Workman,Keikawus Arastéh,Anton Pozniak,Goedele De Smedt,Greet Beets,Monika Peeters,Kati Vandermeulen,Brian Woodfall,Richard M. W. Hoetelmans +10 more
TL;DR: The Phase III formulation of etravirine significantly improves the bioavailability of etavirine over the Phase II formulation with reduced interpatient variability in etravIRine pharmacokinetics.
42
Virological response with fully active etravirine (ETR; TMC125) after 48 weeks of treatment: pooled results from the DUET-1 and DUET-2 trials
Nathan Clumeck,B Clotet,Margaret Johnson,Monika Peeters,Johan Vingerhoets,Greet Beets,G De Smedt +6 more
TL;DR: HIV-1-infected, treatment-experienced patients with documented NNRTI-resistance, ≥3 primary PI mutations and viral load (VL) >5000 copies/mL were randomised 1:1 to receive ETR 200 mg BID or placebo following a meal plus a background regimen of darunavir/ritonavir, NRTI(s) and optional ENF.
Reduction in AIDS defining events/deaths with etravirine (ETR; TMC125) compared to placebo: pooled DUET 48-week results
Richard Haubrich,Joseph J. Eron,Melanie A. Thompson,Peter Reiss,Rainer Weber,Monika Peeters,R Van Solingen-Ristea,Greet Beets,E Voorspoels,G De Smedt +9 more
TL;DR: Etravirine demonstrated durable efficacy and safety in HIV-1 infected, treatment-experienced patients in the phase III DUET trials, and adjudicated clinical end-points from a prespecified pooled analysis of DUET-1 and DUet-2 after 48 weeks of treatment are reported.